Genovis: ADC-related license agreement - Redeye

Redeye updates on Genovis following a new announcement. The company has signed a licensing agreement for its EndoS2 enzyme technology, with potential milestone payments of up to USD20m per project. The deal further strengthens the long-term story and highlights the embedded optionality in the business model.

Länk till analysen i sin helhet: https://www.redeye.se/research/1158258/genovis-adc-related-license-agreement?utm_source=finwire&utm_medium=RSS